Stem cell therapy for Parkinson's disease: where do we stand?

Laurent Roybon, Nicolaj Christophersen, Patrik Brundin, Jia-Yi Li

Research output: Contribution to journalReview articlepeer-review


A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.
Original languageEnglish
Pages (from-to)261-273
JournalCell and Tissue Research
Issue number1
Publication statusPublished - 2004

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Wallenberg Neuroscience Centre, Lund (0131000110), Neuronal Survival (013212041), Neural Plasticity and Repair (013210080)

Subject classification (UKÄ)

  • Cell Biology

Free keywords

  • Parkinson's disease
  • Neural grafting
  • Embryonic stem cells
  • Somatic adult stem cells


Dive into the research topics of 'Stem cell therapy for Parkinson's disease: where do we stand?'. Together they form a unique fingerprint.

Cite this